Prevention of bone loss by bisphosphonate YM175 in ovariectomized dogs with dietary calcium restriction

Japanese Journal of Pharmacology

Volumn 71, Issue 3, 1996, Pages 239-246

  Motoie, Hiroyuki ^a   Kanoh, Hiroyuki ^a   Ogata, Stig ^a   Kawamuki, Kosei ^a   Shikama, Hisataka ^a   Fujikura, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Bisphosphonate; Bone mineral density; Dietary calcium restriction; Ovariectomy; YM175

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; HYDROXYPROLINE; INCADRONIC ACID; NITROGEN; OSTEOCALCIN; PHOSPHATE; PROTEIN; UREA;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CHEMISTRY; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM DEFICIENCY; CALCIUM INTAKE; CONTROLLED STUDY; DOG; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FORELIMB; HYDROXYPROLINE URINE LEVEL; LUMBAR SPINE; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

EID: 0029810031     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.71.239     Document Type: Article

References (34)

1. Riggs BL and Melton LJ III: Involutional osteoporosis. N Engl J Med 314, 1676-1686 (1986)
2. Dempster DW and Lindsay R: Pathogenesis of osteoporosis. Lancet 341, 797-805 (1993)
3. Kalu DN: The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15, 175-192 (1991)
4. Wronski TJ, Dann LM, Scott KS and Cinton M: Long-term effect of ovariectomy and aging on the rat skeleton. Calcif Tissue Int 45, 360-366 (1989)
5. Mosekilde L, Danielsen CC and Knudsen UB: The effect of aging and ovariectomy on the vertebral bone mass and biomechanical properties of mature rats. Bone 14, 1-6 (1993)
6. Sontag W: Quantitative measurement of periosteal and cortical-endosteal bone formation and resorption in the midshaft of female rat femur. Bone 7, 55-62 (1986)
7. Martin RB, Butcher RL, Sherwood LL, Buckendahl P, Boyd RD, Farris D, Sharkey N and Dannucci G: Effects of ovariectomy in beagle dogs. Bone 8, 23-31 (1987)
8. Malluche HH, Faugere M-C, Rush M and Friedler R: Osteoblastic insufficiency is responsible for maintenance of osteopenia after loss of ovarian function in experimental beagle dogs. Endocrinology 119, 2649-2654 (1986)
9. Faugere M-C, Friedler RM, Fanti P and Malluche HH: Bone changes occurring early after cessation of ovarian function in beagle dogs: a histomorphometric study employing sequential biopsies. J Bone Miner Res 5, 263-272 (1990)
10. Dannucci GA, Martin RB and Patterson-Buckendahl P: Ovariectomy and trabecular bone remodeling in the dog. Calcif Tissue Int 40, 194-199 (1987)
11. Boyce RW, Franks AF, Jankowsky ML, Orcutt CM, Piacquadio AM, White JM and Bevan JA: Sequential histomorphometric changes in cancellous bone from ovariectomized dogs. J Bone Miner Res 5, 947-953 (1990)
12. Shen V, Dempster DW, Birchman R, Mellish RWE, Church E, Kohn D and Lindsay R: Lack of changes in histomorphometric, bone mass, and biochemical parameters in ovario-hysterectomized dogs. Bone 13, 311-316 (1992)
13. 3. Calcif Tissue Int 50, 221-227 (1992)
14. Hodgkinson A, Aaron J, Horsman A, McLachlan MSF and Nordin BEC: Effect of oophorectomy and calcium deprivation on bone mass in the rat. Clin Sci Mol Med 54, 439-446 (1978)
15. Kalu DN, Liu CC, Hardin RR and Hollis BW: The aged rat model of ovarian hormone deficiency bone loss. Endocrinology 124, 7-16 (1989)
16. Mosekilde L, Weisbrode SE, Safron JA, Stills HF, Jankowsky ML, Ebert DC, Danielsen CC, Soggard CH, Franks AF, Stevens ML, Paddock CL and Boyce RW: Evaluation of the skeletal effect of combined mild dietary calcium restriction and ovariectomy in Sinclair S-1 minipigs. A pilot study. J Bone Miner Res 8, 1311-1321 (1993)
17. Schenk R, Eggli P, Fleisch H and Rosini S: Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38, 342-349 (1986)
18. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E and Rodan GA: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultra-structure. J Clin Invest 88, 2095-2105 (1991)
19. Ralston SH, Patel U, Fraser WD, Gallacher SJ, Dryburgh FJ, Cowan RA and Boyle IT: Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 2, 1180-1182 (1989)
20. Siris ES, Sherman WH, Baquiran DC, Schlatterer JP, Osserman EF and Camfield RE: Effect of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med 302, 310-315 (1980)
21. O'Doherty DP, Bickerstaff DR, McCloskey EV, Hamdy NAT, Beneton MNC, Harris S, Mian M and Kanis JA: Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res 5, 483-491 (1990)
22. Reginster JY, Deroisy R, Denis D, Collette J, Lecart MP, Sarlet N, Ethgen D and Franchimont P: Prevention of postmenopausal bone loss by tiludronate. Lancet 2, 1469-1471 (1989)
23. Storm T, Thamsborg G, Steiniche T, Genant HK and Sorensen OH: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322, 1265-1271 (1990)
24. Nagao Y, Ishitobi Y, Fukushima S, Kinoshita H, Kawashima H and Kumegawa M: YM175 inhibits osteoclast differentiation and bone resorting action of mature osteoclast. J Bone Miner Res 5, Supp 2, S159 (1990)
25. Kawamuki K, Abe T, Kudoh M, O'uchi N, Motoie H, Usui T, Isomura Y, Takeuchi M and Kawashima H: Effect of YM175 on bone positively correlates with its concentration in bone. J Bone Miner Res 5, Supp 2, S245 (1990)
26. Kudoh M, Abe T, Kawamuki K, Yamaoka E, Isomura Y, Takeuchi M and Kawashima H: Effect of YM175 on experimental hypercalcemia and tumor-induced osteolysis in rats. J Bone Miner Res 5, Supp 2, S166 (1990)
27. Motoie H, Nakamura T, O'uchi N, Nishikawa H, Kanoh H, Abe T and Kawashima H: Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction. J Bone Miner Res 10, 910-920 (1995)
28. Patterson-Allen P, Brautigam CE, Grindeland RE, Asling CW and Callahan PX: A specific radioimmunoassay for osteocalcin with advantageous species cross-reactivity. Anal Biochem 120, 1-7 (1982)
29. Goverde BC and Veenkamp FJN: Routine assay of total hydroxyproline based on resin-catalysed hydrolysis. Clin Chim Acta 41, 29-40 (1972)
30. Parfitt AM: The physiologic and clinical significance of bone histomorphometric data. In Bone Histomorphometry. Techniques and Interpretations, Edited by Recker RR, pp 143-223, CRC Press, Inc, Boca Raton (1983)
31. 3 administration in beagles. Calcif Tissue Int 52, 49-56 (1993)
32. Fleisch H: Bisphosphonates; Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42, 919-944 (1991)
33. Trechsel U, Eisman JA, Fischer JA, Bonjour J-P and Fleisch H: Calcium-dependent, parathyroid hormone-independent regulation of 1,25-dihydroxyvitamin D. Am J Physiol 239, E119-E124 (1980)
34. Jaeger P, Jones W, Clemens TL and Hayslett JP: Evidence that calcitonin stimulates 1,25-dihydroxyvitamin D production and intestinal absorption of calcium in vivo. J Clin Invest 78, 456-461 (1986)